Blockage of interleukin-1β with canakinumab in patients with Covid-19

Abstract There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinum...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lorenza Landi, Claudia Ravaglia, Emanuele Russo, Pierluigi Cataleta, Maurizio Fusari, Andrea Boschi, Diana Giannarelli, Francesca Facondini, Ilaria Valentini, Ilaria Panzini, Luigi Lazzari-Agli, Paolo Bassi, Elisa Marchionni, Rossella Romagnoli, Raffaella De Giovanni, Marina Assirelli, Federica Baldazzi, Fabio Pieraccini, Giovanna Rametta, Lucia Rossi, Luca Santini, Ivana Valenti, Federico Cappuzzo
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c6f76dd0ab04416d8577e6754667f409
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6f76dd0ab04416d8577e6754667f409
record_format	dspace
spelling	oai:doaj.org-article:c6f76dd0ab04416d8577e6754667f4092021-12-02T12:33:15ZBlockage of interleukin-1β with canakinumab in patients with Covid-1910.1038/s41598-020-78492-y2045-2322https://doaj.org/article/c6f76dd0ab04416d8577e6754667f4092020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-78492-yhttps://doaj.org/toc/2045-2322Abstract There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 mg sc). Median time from diagnosis of Covid-19 by viral swab to administration of canakinumab was 7.5 days (range 0–30, IQR 4–11). Median PaO2/FiO2 increased from 160 (range 53–409, IQR 122–210) at baseline to 237 (range 72–533, IQR 158–331) at day 7 after treatment with canakinumab (p < 0.0001). Improvement of oxygen support category was observed in 61.4% of cases. Median duration of hospitalization following administration of canakinumab was 6 days (range 0–30, IQR 4–11). At 7 days, 58% of patients had been discharged and 12 (13.6%) had died. Significant differences between baseline and 7 days were observed for absolute lymphocyte counts (mean 0.60 vs 1.11 × 109/L, respectively, p < 0.0001) and C-reactive protein (mean 31.5 vs 5.8 mg/L, respectively, p < 0.0001).Overall survival at 1 month was 79.5% (95% CI 68.7–90.3). Oxygen-support requirements improved and overall mortality was 13.6%. Confirmation of the efficacy of canakinumab for Covid-19 warrants further study in randomized controlled trials.Lorenza LandiClaudia RavagliaEmanuele RussoPierluigi CataletaMaurizio FusariAndrea BoschiDiana GiannarelliFrancesca FacondiniIlaria ValentiniIlaria PanziniLuigi Lazzari-AgliPaolo BassiElisa MarchionniRossella RomagnoliRaffaella De GiovanniMarina AssirelliFederica BaldazziFabio PieracciniGiovanna RamettaLucia RossiLuca SantiniIvana ValentiFederico CappuzzoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Lorenza Landi Claudia Ravaglia Emanuele Russo Pierluigi Cataleta Maurizio Fusari Andrea Boschi Diana Giannarelli Francesca Facondini Ilaria Valentini Ilaria Panzini Luigi Lazzari-Agli Paolo Bassi Elisa Marchionni Rossella Romagnoli Raffaella De Giovanni Marina Assirelli Federica Baldazzi Fabio Pieraccini Giovanna Rametta Lucia Rossi Luca Santini Ivana Valenti Federico Cappuzzo Blockage of interleukin-1β with canakinumab in patients with Covid-19
description	Abstract There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 mg sc). Median time from diagnosis of Covid-19 by viral swab to administration of canakinumab was 7.5 days (range 0–30, IQR 4–11). Median PaO2/FiO2 increased from 160 (range 53–409, IQR 122–210) at baseline to 237 (range 72–533, IQR 158–331) at day 7 after treatment with canakinumab (p < 0.0001). Improvement of oxygen support category was observed in 61.4% of cases. Median duration of hospitalization following administration of canakinumab was 6 days (range 0–30, IQR 4–11). At 7 days, 58% of patients had been discharged and 12 (13.6%) had died. Significant differences between baseline and 7 days were observed for absolute lymphocyte counts (mean 0.60 vs 1.11 × 109/L, respectively, p < 0.0001) and C-reactive protein (mean 31.5 vs 5.8 mg/L, respectively, p < 0.0001).Overall survival at 1 month was 79.5% (95% CI 68.7–90.3). Oxygen-support requirements improved and overall mortality was 13.6%. Confirmation of the efficacy of canakinumab for Covid-19 warrants further study in randomized controlled trials.
format	article
author	Lorenza Landi Claudia Ravaglia Emanuele Russo Pierluigi Cataleta Maurizio Fusari Andrea Boschi Diana Giannarelli Francesca Facondini Ilaria Valentini Ilaria Panzini Luigi Lazzari-Agli Paolo Bassi Elisa Marchionni Rossella Romagnoli Raffaella De Giovanni Marina Assirelli Federica Baldazzi Fabio Pieraccini Giovanna Rametta Lucia Rossi Luca Santini Ivana Valenti Federico Cappuzzo
author_facet	Lorenza Landi Claudia Ravaglia Emanuele Russo Pierluigi Cataleta Maurizio Fusari Andrea Boschi Diana Giannarelli Francesca Facondini Ilaria Valentini Ilaria Panzini Luigi Lazzari-Agli Paolo Bassi Elisa Marchionni Rossella Romagnoli Raffaella De Giovanni Marina Assirelli Federica Baldazzi Fabio Pieraccini Giovanna Rametta Lucia Rossi Luca Santini Ivana Valenti Federico Cappuzzo
author_sort	Lorenza Landi
title	Blockage of interleukin-1β with canakinumab in patients with Covid-19
title_short	Blockage of interleukin-1β with canakinumab in patients with Covid-19
title_full	Blockage of interleukin-1β with canakinumab in patients with Covid-19
title_fullStr	Blockage of interleukin-1β with canakinumab in patients with Covid-19
title_full_unstemmed	Blockage of interleukin-1β with canakinumab in patients with Covid-19
title_sort	blockage of interleukin-1β with canakinumab in patients with covid-19
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/c6f76dd0ab04416d8577e6754667f409
work_keys_str_mv	AT lorenzalandi blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT claudiaravaglia blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT emanuelerusso blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT pierluigicataleta blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT mauriziofusari blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT andreaboschi blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT dianagiannarelli blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT francescafacondini blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT ilariavalentini blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT ilariapanzini blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT luigilazzariagli blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT paolobassi blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT elisamarchionni blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT rossellaromagnoli blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT raffaelladegiovanni blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT marinaassirelli blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT federicabaldazzi blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT fabiopieraccini blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT giovannarametta blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT luciarossi blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT lucasantini blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT ivanavalenti blockageofinterleukin1bwithcanakinumabinpatientswithcovid19 AT federicocappuzzo blockageofinterleukin1bwithcanakinumabinpatientswithcovid19
_version_	1718393884223995904

Blockage of interleukin-1β with canakinumab in patients with Covid-19

Ejemplares similares